API
< Back to all clusters
[HEALTH] · United States · 2 sources

started · updated

University of California, Riverside researchers test protein therapy for Fragile X syndrome

Researchers at the University of California, Riverside, have launched a new project to investigate whether a protein-based therapy can correct abnormal brain activity linked to Fragile X syndrome. The research is supported by a $100,000 one-year grant from the FRAXA Research Foundation.

Fragile X syndrome, which affects approximately 100,000 Americans, is caused by mutations in the FMR1 gene that impact the production of the FMRP protein. This condition can lead to intellectual disabilities, learning and memory difficulties, and social or behavioral challenges. It is also a significant genetic cause of autism spectrum disorder.

Led by Dr. Devin Binder, the study will utilize a mouse model to test protein candidates developed by the biotechnology company Bowen’s FX Therapeutics. These engineered proteins are designed to replace the function of the missing or impaired proteins in those affected by the disorder. Dr. Binder noted that recent advances in protein engineering now allow for the delivery of therapeutic proteins into the brain, a feat previously considered nearly impossible.

Entities

Bowen’s FX Therapeutics · Devin Binder · FRAXA Research Foundation · University of California, Riverside